



X

D.C.
7-31-02

Patent
Attorney's Docket No. 011900-309

9/105

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Yoshikatsu KODAMA et al.

Application No.: 09/833,637

Filed: April 13, 2001

For: GLYCOPROTEIN HAVING
INHIBITORY ACTIVITY AGAINST
HELICOBACTER PYLORI
COLONIZATION

)
)
) Group Art Unit: 1653

)
) Examiner: C. Kam

)
) Confirmation No. 3072

RECEIVED

JUL 11 2002

TECH CENTER 1600/2900

**INFORMATION DISCLOSURE STATEMENT
TRANSMITTAL LETTER**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Enclosed is an Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

☒ No additional fee for submission of an IDS is required.

☐ The fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) is also enclosed.

☐ A certification under 37 C.F.R. § 1.97(e) is also enclosed.

☐ A certification under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) are also enclosed.

☐ Charge \$_____ to Deposit Account No. 02-4800 for the fee due.


☐ A check in the amount of \$_____ is enclosed for the fee due.

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

By: 
Susan M. Dadio
Registration No. 40,373

Date: July 9, 2002



Patent
Attorney's Docket No. 011900-309

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
Yoshikatsu KODAMA et al.) Group Art Unit: 1653
Application No.: 09/833,637) Examiner: C. Kam
Filed: April 13, 2001) Confirmation No. 3072
For: GLYCOPROTEIN HAVING)
INHIBITORY ACTIVITY AGAINST)
HELICOBACTER PYLORI)
COLONIZATION)

RECEIVED
JUL 11 2002
TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed. A copy of the corresponding European Search Report is also enclosed.

U.S. PATENTS

1. RANDALL et al., U.S. Patent No. 5,116,821, issued on May 26, 1992.

OTHER DOCUMENTS

1. WEBB et al., "Fundamentals of Dairy Chemistry", 1988, Avi Publishing Co., Westport, Ct., Abstract No. XP002195230, pps. 103-105.
2. SHAUER, "Novel infection protection agent against Helicobacter pylori microbe for pharmaceutical and food products - consists of iron bonding type lactoferrin active ingredient for opposing specific pylori microbe", 1999, Derwent Publications Ltd., London, England, Abstract No. XP002195231.
3. SNOW BRAND MILK PROD. CO. LTD., "Agent for treating stomach and intestine - contains lactoferrin", 1998, Derwent Publications Ltd., London, England, Abstract No. XP002195232.


4. ICATLO et al., "Affinity Purification of Helicobacter pylori Unrease", *The Journal of Biological Chemistry*, 1998, pp. 18130-38, vol. 273, no. 29, John Wiley & Sons, New York, New York.
 5. YAMAZAKI et al., "Antibacterial Effects of Lactoferrin and a Pepsin-Generated Lactoferrin Peptide against Helicobacter pylori in vitro," *Journal of Infect. Chemother.*, 1997, pp. 85-89, vol. 3.
 6. WADA et al., "The Therapeutic Effect of Bovine Lactoferrin in the Host Infected with Helicobater pylori," *Scandinavian Journal of Gastroenterology*, 1999, pp. 238-243, vol. 34, no. 3.
 7. HIRMO et al., "Inhibition of Helicobacter pylori sialic acid-specific haemagglutination by human gastrointestinal mucins and milk glycoproteins," *FEMS Immunology and Medical Microbiology*, 1998, pp. 275-281, vol. 20, no. 4, Elsevier Science B.V., Amsterdam, Netherlands.
 8. DIAL et al., "Antibiotic Properties of Bovine Lactoferrin on Helicobacter pylori," *Digestive Diseases and Sciences*, 1998, pp. 2750-56, vol. 43, no. 12.
-

I, the undersigned, hereby state that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. Therefore, no fee is due.

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: 
Susan M. Dadio
Registration No. 40,373

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Date: July 9, 2002
